Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

AbbVie CF Scholarship program presents annual academic awards to 40 student scholars

AbbVie today announced the 40 outstanding students with cystic fibrosis (CF) who will each receive $2,500 to pursue their undergraduate or graduate school education during the 2014-2015 school year through the AbbVie CF Scholarship program.

19 Aug 2014

UI scientists discover that CF mucus abnormality is present at birth

Mucus is key to keeping our lungs clean and clear of bacteria, viruses, and other foreign particles that can cause infection and inflammation. When we inhale microbes and dust, they are trapped in the mucus and then swept up and out of the lungs via a process called mucociliary transport.

16 Aug 2014

New x-ray imaging system helps monitor effectiveness of treatment for cystic fibrosis

Scientists have developed an x-ray imaging system that enables researchers to see 'live' how effective treatments are for cystic fibrosis.

16 Aug 2014

Researchers develop new lung-on-chip model for laboratory studies of respiratory challenges

Researchers at RTI International, in collaboration with the University of North Carolina at Chapel Hill, have developed a new lung-on-chip microdevice for laboratory studies of respiratory challenges and therapeutics. The microdevice includes multiple vertically stacked cellular layers that mimic the structure of the airway tissue.

15 Aug 2014

Researchers create synthetic ion transporter that triggers apoptosis in cancer cells

Researchers from the University of Southampton are part of an international team that has helped to create a molecule that can cause cancer cells to self-destruct by carrying sodium and chloride ions into the cells.

12 Aug 2014

Researchers create synthetic molecule that can cause cancer cells to self-destruct

Researchers from The University of Texas at Austin and five other institutions have created a molecule that can cause cancer cells to self-destruct by ferrying sodium and chloride ions into the cancer cells.

12 Aug 2014

Experts explain pros and cons of over-the-counter enzymes

Enzyme supplements available without a prescription are becoming increasingly popular, but should everyone add them to their shopping list? Brent Bauer, M.D., director of the Mayo Clinic Complementary and Integrative Medicine Program, is co-author of a new paper in the medical journal Mayo Clinic Proceedings on the pros and cons of over-the-counter enzymes.

5 Aug 2014

Computational biologists develop program for easy diagnosis of hereditary illnesses

In the case of a cough or a sore throat, the doctor can usually diagnose a common cold immediately. However, the diagnosis of hereditary illnesses like cystic fibrosis, which affects the metabolism, or Huntington's disease, which leads to cognitive decline, is much more complex.

29 Jul 2014

NC Senate plan to overhaul state Medicaid program draws fire from doctors and hospitals

The North Carolina plan was presented by state senators during a Wednesday meeting of the Senate Rules and Operations Committee.

18 Jul 2014

First Edition: July 17, 2014

Today's headlines include reports about how Capitol Hill politics are impacting health care policy. Houston Public Media's Carrie Feibel, working in partnership with Kaiser Health News and NPR, reports: "Primary care doctors have reported problems making referrals for patients who have purchased some of the cheaper plans from the federal insurance marketplace.

17 Jul 2014

PTC Therapeutics initiates reimbursed expanded access program for Translarna

PTC Therapeutics, Inc. today announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to make Translarna (ataluren) available to patients before commercial availability in certain countries.

9 Jul 2014

Children who undergo simple emergency surgeries on weekends are more likely to die

Children who undergo simple emergency surgeries, such as hernia repairs or appendix removals, on weekends are more likely to suffer complications and even die than children getting the same kind of treatment during the week, according to results of a Johns Hopkins Children's Center study.

1 Jul 2014

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

Queen's doctor plays key role in major breakthrough to change lives of cystic fibrosis sufferers

A Queen's University doctor has played a key role in a major breakthrough to change the lives of cystic fibrosis sufferers.

26 Jun 2014

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Forest Laboratories, Inc. today announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety disorder (GAD).

24 Jun 2014

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm Corporation ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE).

23 Jun 2014

Celsus’ expert highlights serious side effects of topical corticosteroids

A 2013 Mayo Clinic study involving more than 140,000 patients revealed that skin disorders are the most common nonacute reason Americans seek health care.

9 Jun 2014

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm Corporation is pleased to announce that its common shares have been approved for listing on the NASDAQ Capital Market.

9 Jun 2014

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Many people with cystic fibrosis develop diabetes. The reasons for this have been largely unknown, but now researchers at Lund University in Sweden and  Karolinska institutet have identified a molecular mechanism that contributes to the raised diabetes risk.

2 Jun 2014

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet.

31 May 2014

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

AbbVie CF Scholarship program presents annual academic awards to 40 student scholars

UI scientists discover that CF mucus abnormality is present at birth

New x-ray imaging system helps monitor effectiveness of treatment for cystic fibrosis

Researchers develop new lung-on-chip model for laboratory studies of respiratory challenges

Researchers create synthetic ion transporter that triggers apoptosis in cancer cells

Researchers create synthetic molecule that can cause cancer cells to self-destruct

Experts explain pros and cons of over-the-counter enzymes

Computational biologists develop program for easy diagnosis of hereditary illnesses

NC Senate plan to overhaul state Medicaid program draws fire from doctors and hospitals

First Edition: July 17, 2014

PTC Therapeutics initiates reimbursed expanded access program for Translarna

Children who undergo simple emergency surgeries on weekends are more likely to die

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Queen's doctor plays key role in major breakthrough to change lives of cystic fibrosis sufferers

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Celsus’ expert highlights serious side effects of topical corticosteroids

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in